Lalashowi J, Mvungi H, Mwaisango Z, Pamba D, Mohamed A, Gitige C
BMJ Open. 2025; 15(3):e088556.
PMID: 40037680
PMC: 11881200.
DOI: 10.1136/bmjopen-2024-088556.
Mulaku M, Owino E, Ochodo E, Young T
F1000Res. 2025; 13:1436.
PMID: 39816981
PMC: 11733733.
DOI: 10.12688/f1000research.157439.1.
Vibulchai N, Dana K, Sanchan M, Churari C, Jadboonnak B, Sawangsri W
Belitung Nurs J. 2024; 10(4):408-415.
PMID: 39211457
PMC: 11350345.
DOI: 10.33546/bnj.3327.
Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A, Galindo M
J Clin Tuberc Other Mycobact Dis. 2024; 35:100433.
PMID: 38617837
PMC: 11015490.
DOI: 10.1016/j.jctube.2024.100433.
Nagarajan K, Kumarswamy K, Begum R, Panibatla V, Singarajipura A, Adepu R
Lancet Reg Health Southeast Asia. 2024; 22:100372.
PMID: 38420270
PMC: 10900834.
DOI: 10.1016/j.lansea.2024.100372.
A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT).
Karnan A, Jadhav U, Ghewade B, Ledwani A, Shivashankar P
Cureus. 2024; 16(1):e52706.
PMID: 38384625
PMC: 10879947.
DOI: 10.7759/cureus.52706.
mHealth application for improving treatment outcomes for patients with multidrug-resistant tuberculosis in Vietnam: an economic evaluation protocol for the V-SMART trial.
Cheng Q, Dang T, Nguyen T, Velen K, Nguyen V, Nguyen B
BMJ Open. 2023; 13(12):e076778.
PMID: 38081668
PMC: 10729151.
DOI: 10.1136/bmjopen-2023-076778.
Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study.
Dickson L, Le Roux S, Mitrani L, Hill J, Jassat W, Cox H
BMJ Open. 2023; 13(11):e067121.
PMID: 37977868
PMC: 10660906.
DOI: 10.1136/bmjopen-2022-067121.
Successful outcomes for patients with drug-resistant tuberculosis despite civil unrest and COVID-19 in Haiti.
Vilbrun S, Souroutzidis A, Walsh K, Ellis J, Guiteau C, Delva S
PLOS Glob Public Health. 2023; 3(9):e0002356.
PMID: 37698996
PMC: 10497149.
DOI: 10.1371/journal.pgph.0002356.
Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis.
Choi H, Mok J, Kang Y, Jeong D, Kang H, Kim H
ERJ Open Res. 2023; 9(4).
PMID: 37583964
PMC: 10423986.
DOI: 10.1183/23120541.00135-2023.
Psychosocial support interventions to improve treatment outcomes for people living with tuberculosis: a mixed methods systematic review and meta-analysis.
Maynard C, Tariq S, Sotgiu G, Migliori G, Boom M, Field N
EClinicalMedicine. 2023; 61:102057.
PMID: 37457116
PMC: 10338299.
DOI: 10.1016/j.eclinm.2023.102057.
Impacts of Medical Security Level on Treatment Outcomes of Drug-Resistant Tuberculosis: Evidence from Wuhan City, China.
Liu X, Lin K, Li Y, Jiang J, Zhong Z, Xiong Y
Patient Prefer Adherence. 2022; 16:3341-3355.
PMID: 36573226
PMC: 9789709.
DOI: 10.2147/PPA.S389231.
A Dual Perspective of Psycho-Social Barriers and Challenges Experienced by Drug-Resistant TB Patients and Their Caregivers through the Course of Diagnosis and Treatment: Findings from a Qualitative Study in Bengaluru and Hyderabad Districts of South....
Nagarajan K, Kumarsamy K, Begum R, Panibatla V, Reddy R, Adepu R
Antibiotics (Basel). 2022; 11(11).
PMID: 36358241
PMC: 9686660.
DOI: 10.3390/antibiotics11111586.
Patient and health-care provider experience of a person-centred, multidisciplinary, psychosocial support and harm reduction programme for patients with harmful use of alcohol and drug-resistant tuberculosis in Minsk, Belarus.
Harrison R, Shyleika V, Falkenstein C, Garsevanidze E, Vishnevskaya O, Lonnroth K
BMC Health Serv Res. 2022; 22(1):1217.
PMID: 36180873
PMC: 9523183.
DOI: 10.1186/s12913-022-08525-x.
Causes of loss to follow-up from drug-resistant TB treatment in Khayelitsha, South Africa.
Memani B, Beko B, Dumile N, Mohr-Holland E, Daniels J, Sibanda B
Public Health Action. 2022; 12(2):55-57.
PMID: 35734003
PMC: 9176197.
DOI: 10.5588/pha.21.0083.
Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
Adamashvili N, Baliashvili D, Kuchukhidze G, Salindri A, Kempker R, Blumberg H
Int J Tuberc Lung Dis. 2022; 26(4):326-333.
PMID: 35351237
PMC: 9757601.
DOI: 10.5588/ijtld.21.0450.
New developments in tuberculosis diagnosis and treatment.
Gill C, Dolan L, Piggott L, McLaughlin A
Breathe (Sheff). 2022; 18(1):210149.
PMID: 35284018
PMC: 8908854.
DOI: 10.1183/20734735.0149-2021.
Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa.
Reuter A, Beko B, Memani B, Furin J, Daniels J, Rodriguez E
Trop Med Infect Dis. 2022; 7(2).
PMID: 35202216
PMC: 8879094.
DOI: 10.3390/tropicalmed7020021.
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS.
ODonnell M, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C
J Acquir Immune Defic Syndr. 2022; 90(3):325-332.
PMID: 35195572
PMC: 11077859.
DOI: 10.1097/QAI.0000000000002940.
Public health and hospital-based nursing intersection: Case study of drug-resistant tuberculosis patients.
Pietersen E, Anderson K, van der Heijden Y
Public Health Nurs. 2022; 39(1):170-179.
PMID: 34990027
PMC: 8766955.
DOI: 10.1111/phn.13042.